Compare Revvity Inc (RVTY) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs SOLAI Limited — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Revvity Inc is far larger — about 773.5× SOLAI Limited's market cap, and Revvity Inc pays a 0.24% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| RVTY | SLAI | |
|---|---|---|
Market Cap | $12.91B | $16.69M |
Sector | Technology | Technology |
52-Week High | $117.75 | $26.74 |
52-Week Low | $82.26 | $2.74 |
Enterprise Value | $15.23B | $16.33M |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.
The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
